Rafael Torgovicky, Md

AiCure is an AI and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. AiCure improves predictability of study timelines, reduces costs and accelerates timelines through remote patient engagement and assessments, including measuring digital biomarkers and real-time monitoring of patient dosing. Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has more than 65 issued patents and works with global clients in over 30 countries. AiCure is globally recognized and is a recipient of the Scrip Award, AI 100 and Digital Health 150. For more information, please visit www.aicure.com.

AiCure is an AI and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. AiCure improves predictability of study timelines, reduces costs and accelerates timelines through remote patient engagement and assessments, including measuring digital biomarkers and real-time monitoring of patient dosing. Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has more than 65 issued patents and works with global clients in over 30 countries. AiCure is globally recognized and is a recipient of the Scrip Award, AI 100 and Digital Health 150. For more information, please visit www.aicure.com.

Accelmed Partners is a lower middle-market private equity firm focused on acquiring and investing in U.S. commercial-stage HealthTech companies. For more than a decade, we have leveraged our deep HealthTech industry experience, operational and financial expertise, and strong relationships to help management teams at companies across the medical device, tools, diagnostics, digital health and tech-enabled services sectors position their businesses for future growth and success. Our ideal partners share our values of integrity, transparency and tenacity, directed toward leveraging technology to improve patient outcomes, reduce costs and increase efficiency throughout the healthcare system. We currently manage over $630 million of equity capital and are actively investing out of our second private equity fund, Accelmed Partners II.

Israel Biotech Fund – Building the future of Israeli Biotech Israel Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies. Based in Rehovot, Israel’s main Biotech hub, we invest exclusively in Biotech companies developing drugs at or near clinical stages. Our partners include two top-tier international pharmaceuticals companies, institutional investors, family offices and high net worth individuals. Our key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support. We don’t just invest in promising companies – we have the ability, experience and network required to identify the best opportunities and partner with our portfolio companies to help them go the distance. We provide our portfolio companies with the necessary resources for long-term sustainable growth. This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities. The biotechnology industry in Israel is growing with enormous potential and we are determined to realize its full potential and real value. Team General Partners: David Sidransky, M.D., co-founder and general partner of Israel Biotech Fund. Yuval Cabilly, Ph.D., co-founder and general partner of Israel Biotech Fund. Ido Zairi, co-founder and general partner of Israel Biotech Fund. Venture Advisors Our key members include: Sol Barer, Ph.D., former Chairman and CEO of Celgene, currently serves on the board of several Biotech companies, including TEVA. Jeff Kindler, former Chairman & CEO of Pfizer. Robert Spiegel, MD, former Chief Medical Officer of Schering-Plough. Murray A. Goldberg, former CFO of Regeneron.